Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Generics Bulletin Editor’s Picks For Q3 2021

Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.

Generic Drugs Biosimilars

Teligent Cites Remediation-Related Activites For Poor Quarter

New Jersey-based Teligent reported a low quarter as the company continues to focus on remediation measures to lift the FDA warning letter hanging over its Buena New Jersey manufacturing facilty. Teligent has also recently recalled a batch of its 4% lidocaine hydrochloride topical solution because the firm’s testing found it to be super potent.

Generic Drugs Sales & Earnings

Alkem Delivers Strong Quarter With Domestic Recovery

India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.

Sales & Earnings India

Celltrion Recovers With High-Margin US Sales

South Korea’s Celltrion has delivered a strong second quarter on the back of high-margin US sales, as its Truxima rituximab biosimilar recovered. The company is on track to launch at least one biosimilar every year by 2030. Meanwhile, the company and partner Icure have filed a donepezil patch with the Korean Ministry of Food and Drug Safety.

Biosimilars Strategy

Towa Follows Suit With Sawai To Steal Japanese Share From Nichi-Iko

Japanese player Towa Pharmaceutical joined Sawai in capitalizing on Nichi-Iko’s misery by taking market share from its rival, as it ran factories at full capacity and plotted for further expansion.

Sales & Earnings Quality

Japan’s Sawai Benefits In Domestic Market From Rivals’ Supply Misery

Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”

Generic Drugs Manufacturing

Stada Generics Takes A Hit Even As Firm Steals A March On Rivals

Stada saw a small drop in both sales and profitability for its Generics division, but insisted the firm’s “strong position in generics,” alongside its leading position in consumer healthcare and growing specialty offering, “put the group on a sustainable growth course.”

Biosimilars Generic Drugs

Adcock Ingram Eyeing 20 Launches Including 18 Generic Products

Adcock Ingram enjoyed a rise in sales but a dip in profit during its 2020/21 financial year, as the South African firm laid out plans to launch 20 products during its current financial year ending in June 2022, including 18 generics and one new chemical entity.

Generic Drugs Sales & Earnings

Lannett Looks To Transform Company With Five Pipeline Assets

With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio. 

Biosimilars Generic Drugs
UsernamePublicRestriction

Register